000756 新华制药
2025/12 -
人民幣(K¥)

变动
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入8,754,7223.41%8,100,8457,502,9876,560,0786,005,587
减:营业总成本8,390,2135.67%7,530,9057,020,4786,173,7365,585,070
    其中:营业成本7,110,18010.67%5,709,1425,465,6564,786,4104,190,990
               财务费用34,573184.77%16,35132,01952,90383,710
               资产减值损失(47,394)-8.18%(69,283)(43,526)(33,267)(45,159)
公允价值变动收益------------
投资收益7,765-21.06%9,5838,3658,0175,611
    其中:对联营企业和合营企业的投资收益(539)-440.65%1,418447(1,089)(2,978)
营业利润363,985-31.89%534,582476,707425,591422,485
利润总额358,917-32.74%532,686471,774421,233411,638
减:所得税费用52,61312.09%26,57945,66559,15964,525
净利润306,304-37.07%506,107426,110362,074347,113
减:非控股权益16,415-1.65%9,59515,04713,52622,254
股东净利润289,889-38.32%496,512411,063348,548324,860

市场价值指针
每股收益 (元) *0.420-39.13%0.7400.6200.5600.520
每股派息 (元) *0.150-45.45%0.2500.2000.1500.150
每股净资产 (元) *7.5513.24%6.7496.1625.5285.184
审计意见 #标准无保留意见标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容